• <object id="us9qi"><meter id="us9qi"></meter></object>

    <wbr id="us9qi"><menuitem id="us9qi"></menuitem></wbr>

    <source id="us9qi"><nav id="us9qi"></nav></source>

  • EN|About Us
    Our History

    About Us

    Our History

    Home>About Us>Our History
    2021

    In November 2021, CR Pharmaceutical fully completed the acquisition of Boya Bio-pharmaceutical, with a shareholding ratio of 28.86% and a voting right of 40.01%, realizing a strategic development in the field of blood products. 

    In September 2021, CR Jiangzhong acquired a 51% stake in Hays Pharma Limited, adding high-quality varieties to its original gastroenterology products. 

    In July 2021, CR Pharmaceutical acquired a 10% stake in Immunotech Biopharm Ltd. for strategic development in the field of cellular immunotherapy. 

    In February 2021, CR Double-Crane acquired a 33.3% stake in Zhejiang Peptites Biotech Co., Ltd. by means of capital increase, establishing its presence in the peptide field. 

     
    2020

    The class I innovative drug NIP046 developed by CR Pharmaceutical was approved for clinical trial targeting rheumatoid arthritis indications. 

    The class I innovative drug NIP292 obtained the Orphan Drug Designation (ODD) issued by the Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF). 

    CR Double-Crane acquired 38.75% of the stake of Dongying Tiandong Pharmaceutical Co., Ltd. 

     
    2019

    CR Pharmaceutical completed the reorganization of CR Jiangzhong. By then, Jiangxi Jiangzhong Pharmaceutical (Group) Co., Ltd. (Jiangzhong Group) was renamed China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (CR Jiangzhong) and was listed as a first-level profit center in CR Pharmaceutical’s management sequence. 

    CR Sanjiu, CR Double-Crane, and Dong-E-E-Jiao were officially included in the FTSE Russell Global Index. 

    The class I innovative drug NIP292 for the treatment of idiopathic pulmonary fibrosis (IPF) obtained the approval of FDA for Phase I clinical trial. 

    CR Double-Crane held a meeting for celebrating the company’s 80th anniversary of its foundation in Beijing.  

     
    2018

    CR signed a strategic cooperation agreement with the People’s Government of Jiangxi for the reorganization of Jiangzhong Group. CR Pharmaceutical acquired or subscribed over 51% stake of Jiangzhong Group equity through cash or assets. 

    CR Pharmaceutical was selected as a constituent stock of the Hang Seng Corporate Sustainability Benchmark Index. 

    CR Sanjiu and Dong-E-E-Jiao were listed in the MSCI Emerging Market Index. 

    CR Double-Crane acquired Hunan Xiangzhong Pharmaceutical Co., Ltd. 

     
    2017

    CR Pharmaceutical was listed as a constituent stock in the Hang Seng Composite LargeCap Index, the Hang Seng Mainland Healthcare Index, the Hang Seng Healthcare Index, the Hang Seng China-Affiliated Corporations Index, the Hang Seng China (Hong Kong-listed) 100 Index, the FTSE Global Equity Index Series (Large Cap), the FTSE All-World Index Series, the FTSE Global All Cap Index, and the MSCI China Index.

    CR Sanjiu acquired 65% of the equity of Jilin Jinfukang Pharmaceutical Co., Ltd. and 65% of the equity of Shandong Shenghai Health Products Co., Ltd. CR Double-Crane acquired 100% of the equity of Hainan Zhong Hua Lian He Pharmaceutical. Co., Ltd. 

     
    2016

    We completed the acquisition of 100% interest in CR Pharmaceutical Retail Group which wholly owned CR Care, a company principally engaged in pharmacy business in China and Hong Kong.

    2015

    CR Pharmaceutical Holdings was awarded the “Top 10 PRC Pharmaceutical Group of 2015 (中國醫藥行業企業集團十強)” at the ChemPharm Annual Summit 2015(2015中國化學制藥行業年度峰會).

    2014

    Our Company ranked No.4 among the “Top 100 Enterprises in the PRC Pharmaceutical Industry of 2013 (2013年度中國醫藥工業百強企業”.

    CR Pharmaceutical Holdings was awarded the “Top 10 PRC Pharmaceutical Group of 2014 (中國醫藥行業企業集團十強)” at the ChemPharm Annual Summit 2014 (2014中國化學制藥行業年度峰會).

    The Beijing Pharmaceutical Group Industry-University-Research Alliance (北京醫藥集團產學研聯盟) led by our Company under the Eleventh-Five Year Plan was successfully completed and accepted.

    2013

    BEID Fund became a shareholder of our Company.

    The total assets and revenue of our Group for the year respectively exceeded HK$100 billion for the first time.

    2012

    CR Pharmaceutical Commercial became a wholly-owned subsidiary of our Company.

    We acquired the remaining 52.72% interest in CR Zizhu to further develop our product portfolio and enhance our market penetration.

    Pharmaceutical R&D Center became our wholly-owned subsidiary.

    We established the Health Institute of China Resources University (華潤大學健康學院) in June 2012.

    2011

    We acquired the remaining 50% interest in Beijing Pharmaceutical, and thereafter Beijing Pharmaceutical became a wholly-owned subsidiary of our company.

    Beijing Pharmaceutical investment became a Share holder of our Company.

    We successfully completed 11 mergers and acquisitions in Beijing, Jiangsu, Henan and other provinces, which further developed our core businesses and enhanced our presence in the pharmaceutical market in China.

    2010

    Our company entered into a strategic cooperation agreement with the China Academy of Medical Sciences (中國醫學科學院) to strengthen the research and development capabilities of our Group.

    We acquired 50% interest in Beijing Pharmaceutical from CRC.

    CR Double-Crane became our non-wholly owned subsidiary following the completion of acquisition of 50% interest in Beijing Pharmaceutical.

    2008

    We acquired 56.62% interest in CR Dong-E from CRC, thereby controlling 23.14% interest in Dong-E-E-Jiao, a company listed on the Shenzhen Stock Exchange and principally engaged in the manufacturing of E Jiao (donkey-hide gelatin) products. 

     We completed the acquisition of 66.98% interest in CR Sanjiu, a company listed on the Shenzhen Stock Exchange and principally engaged in the manufacturing and sale of OTC drugs and Chinese prescription medicine.

    2007

    Our Company was incorporated in Hong Kong.

    2006

    CRC was engaged in the restructuring of China Worldbest, and acquired 50% interest in Beijing Pharmaceutical.

    2004

    CRC set up CR Done-E with Liaocheng SASAC (the State-Owned Assets Supervision and Administration Commission of the State Council).

    1983

    Our controlling shareholder, China Resources Holdings, was incorporated in Hong Kong.

    1953

    China Resources Company (華潤公司) started to export medicines and medical devices to mainland China.

    1948

    Liow & Company (聯合行) was renamed as China Resources Company (華潤公司)

    1938

    Liow & Company (聯合行), the predecessor of China Resources Holdings, our controlling shareholder, was founded.

    Back to Top
    精品国产一区二区三区AV性色_激情性无码视频在线观_一级黄片免费看中文字幕_免费观看18禁国产在线
  • <object id="us9qi"><meter id="us9qi"></meter></object>

    <wbr id="us9qi"><menuitem id="us9qi"></menuitem></wbr>

    <source id="us9qi"><nav id="us9qi"></nav></source>